ArticleBritish journal of cancer2019
Immunomodulatory role of histamine H4 receptor in breast cancer.
Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting histamine signaling: repurposing antihistamines for cancer chemotherapy and immunotherapy.Archives of pharmacal research · 2026Review
- Virtual Screening, Synthesis and In Vitro Characterization of Histamine HInternational journal of molecular sciences · 2026Article
- Regulatory T cells in the breast cancer tumor microenvironment: new mechanisms, potential therapeutic strategies and future perspectives.American journal of cancer research · 2026Review
- Targeting histamine H4 receptor improves anti-tumoral response in a murine model of breast cancer.Frontiers in immunology · 2026Article
- Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.MedComm · 2025Review
- The role of histamine and its receptors in breast cancer: from pathology to therapeutic targets.Medical oncology (Northwood, London, England) · 2024Review
- Expression profile of messenger and micro RNAs related to the histaminergic system in patients with five subtypes of breast cancer.Frontiers in oncology · 2024Article
- Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine.Journal of cancer research and clinical oncology · 2023Article
- Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer.International journal of molecular sciences · 2023Article
- Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.Oncogene · 2023Review
- Anti-neoplastic action of Cimetidine/Vitamin C on histamine and the PI3K/AKT/mTOR pathway in Ehrlich breast cancer.Scientific reports · 2022Article
- Histamine H4 Receptor Expression in Triple-negative Breast Cancer: An Exploratory Study.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- Variances in the Expression of mRNAs and miRNAs Related to the Histaminergic System in Endometrioid Endometrial Cancer.Biomedicines · 2021Article
- Evaluation of the Differences in the Expression of Biogenic Amine-Related mRNAs and Proteins in Endometrioid Endometrial Cancer.Journal of clinical medicine · 2021Article
- The Interplay between Histamine HBiomolecules · 2021Article
- Histamine in cancer immunology and immunotherapy. Current status and new perspectives.Pharmacology research & perspectives · 2021Review
- Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets.Biomolecules · 2021Review
- Tpt1 the balance toward immunosuppression upon cell death.Nature immunology · 2021Article
- Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model.Cancer immunology, immunotherapy : CII · 2021Article
- Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the role of histamine H4 receptor (H4R) in immune cells is being extensively investigated, its immunomodulatory function in cancer is completely unknown. This study aimed to investigate the role of H4R in antitumour immunity in a model of triple-negative breast cancer.
methodsWe evaluated growth parameters, histological characteristics and the composition of tumour, splenic and tumour draining lymph node (TDLN) immune subsets, in a syngeneic model, developed orthotopically with 4T1 cells in H4R knockout (H4R-KO) and wild-type mice.
resultsMice lacking H4R show reduced tumour size and weight, decreased number of lung metastases and percentage of CD4
conclusionsThis is the first report that demonstrates the participation of H4R in antitumour immunity, suggesting that H4R could be a target for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.